UNSPSC 51112900: Alkylating agent triazines

This classification denotes substances consisting of heterocyclic rings that contain three nitrogen atoms at 1,2,4 or 1,3,5 or 2,4,6, substances called triazines, that constitute reactive chemicals that introduce into biologically active molecules alkyl radicals and thereby disrupt functioning of the same, substances called alkyl-ating agents, thus the term ALKYLATING AGENT TRIAZINES.

UNSPSC 51112900 Alkylating agent triazines is a Class code identifying a category of chemotherapy pharmaceuticals. State and local procurement under this code centers on pharmaceutical supply and benefit management through health and human services agencies and Medicaid programs, though the recent activity is sparse and focused on program structure rather than direct drug procurement. The Texas Health and Human Services Commission issued a Request for Information on March 27, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program—a market-intelligence exercise to understand how vendors could establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The scope targets vendors with experience in direct contracting for self-insured employers and government health plans, negotiating net pricing models, and implementing value-based or outcomes-based agreements.

State and local procurement activity under this code is currently minimal. The Texas HHS RFI posted April 3, 2026 (due the same day), represents the only recent solicitation captured. No formal RFPs, RFQs, or ITBs for alkylating agent triazine supply itself appear in the recent record. The RFI is exploratory—designed to inform future procurement strategy rather than commit to contract amounts or timelines—and does not specify set-asides, budget ranges, or incumbent contractor information. Geographic activity is concentrated in Texas. State and local governments typically procure chemotherapy agents through established Medicaid pharmacy benefit channels and state health department formularies; this particular activity signals that Texas may be exploring alternative procurement structures that could reshape how such drugs reach eligible beneficiaries, but no formal competitive opportunity has yet emerged.